<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030274</url>
  </required_header>
  <id_info>
    <org_study_id>Occ2016_06</org_study_id>
    <nct_id>NCT03030274</nct_id>
  </id_info>
  <brief_title>The Prelieve Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients</brief_title>
  <acronym>PRELIEVE</acronym>
  <official_title>Prospective, Non-randomized, Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients With Reduced Ejection Fraction or in Heart Failure Patients With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Occlutech International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Occlutech International AB</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate safety and efficacy of the Occlutech® AFR device in patients&#xD;
      with HFrEF (Heart failure with reduced ejection fraction) and HFpEF (Heart failure with&#xD;
      preserved ejection fraction)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll subjects with HFrEF or HFpEF, until a maximum of 100 patients have&#xD;
      undergone implantation with the Occlutech® AFR device.&#xD;
&#xD;
      Enrolled patients will be stratified according to their ejection fraction as either HFrEF&#xD;
      (ejection fraction &gt; 15% and &lt;40 %) or HFpEF ( ejection Fraktion &gt; 40 % to 70 %). It is&#xD;
      planned to enroll at least 100 patients per stratification subgroup.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Device Effects (SADE) within 3 month following implantation.</measure>
    <time_frame>0-3 month</time_frame>
    <description>Incidence of Serious Adverse Device Effects (SADE) following implantation such as:&#xD;
device dislocation / embolization&#xD;
damage to the tricuspid or mitral valve caused by the device&#xD;
intractable arrhythmias caused by the device&#xD;
any circumstances that require device removal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Device Effects (SADE) between 3-12 month following implantation</measure>
    <time_frame>3-12 month</time_frame>
    <description>Incidence of all Serious Adverse Device Effects (SADE) following implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device placement</measure>
    <time_frame>0-12 month</time_frame>
    <description>Device placement in situ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left to Right shunt through the AFR device</measure>
    <time_frame>0-12 month</time_frame>
    <description>Evidence of Left to Right shunt through the AFR device</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Heart Failure Low Output</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Occlutech AFR Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective, non-randomized, pilot study to assess safety and efficacy of a novel Atrial Flow Regulator in Heart Failure Patients with with reduced Ejection Fraction (HFrEF) and Heart Failure Patients with preserved Ejection Fraction (HFpEF); the AFR-Prelieve Trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occlutech AFR device</intervention_name>
    <description>Catheter-guided placement of an AFR device following balloon atrial septostomy.</description>
    <arm_group_label>Occlutech AFR Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria. Each patient must fulfill ALL of the following criteria and details:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Heart failure resulting in NYHA class III or IV ambulatory&#xD;
&#xD;
          3. Ongoing management of heart failure according to ESC (European Society of Cardiology)&#xD;
             (15) -guidelines during previous ≥6 months&#xD;
&#xD;
          4. Control with Arrhythmia with heart rate &lt;110bpm&#xD;
&#xD;
          5. Life expectancy of at least 1 year&#xD;
&#xD;
          6. The patient should have the ability to fluently speak and understand the language in&#xD;
             which the study is being conducted&#xD;
&#xD;
          7. Written, informed consent by the patient for participation in the study and agreement&#xD;
             to comply with the follow-up schedule&#xD;
&#xD;
          8. Patient has had a successful Balloon Atrial Septostomy (BAS) procedure and is in a&#xD;
             stable hemodynamic state, as assessed by the investigator&#xD;
&#xD;
          9. LVEF ≥15% and ≤ 70% , EF measured via Echocardiography 9.1.9.1. And for LVEF ≥ 40%&#xD;
             (HFpEF): elevated NT-pro-BNP of ≥ 125 pg/ml&#xD;
&#xD;
         10. Elevated left ventricular filling pressure documented by 10.1. Either Pulmonary&#xD;
             capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure at rest ≥&#xD;
             15 mmHg and greater then central venous preassure (CVP) 10.2. 10.2. Or: End-expiratory&#xD;
             PCWP ≥25 mmHg at exercise and CVP &lt;20 mm Hg&#xD;
&#xD;
         11. Transseptal catheterization and femoral vein access is determined to be feasible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Local or generalized sepsis or other acute infection(s)&#xD;
&#xD;
          2. Any coagulation disorder, if clinically relevant in the opinion of the operator.&#xD;
&#xD;
          3. Allergy to nickel and/or titanium and/or nickel/titanium-based materials, if not&#xD;
             medically manageable&#xD;
&#xD;
          4. Allergy to anti-platelet, -coagulant, or -thrombotic therapy, if not medically&#xD;
             manageable&#xD;
&#xD;
          5. Intolerance to contrast agents, if not medically manageable&#xD;
&#xD;
          6. Participation in another medical trial testing a therapy less than 30 days before the&#xD;
             intended AFR implantation procedure&#xD;
&#xD;
          7. Trans-oesophageal echocardiography and / or use of general anaesthetic is&#xD;
             contraindicated&#xD;
&#xD;
          8. Breast feeding women&#xD;
&#xD;
          9. Pregnancy&#xD;
&#xD;
             Processes which would technically disturb the safe intervention as planned:&#xD;
&#xD;
         10. Occluded inferior vena cava access&#xD;
&#xD;
         11. History of ASD and/or atrial septal repair or closure device in place&#xD;
&#xD;
         12. Intracardiac thrombus&#xD;
&#xD;
             Clinical conditions:&#xD;
&#xD;
         13. Moderate valvular diseases requiring therapy according to current ESC guidelines.&#xD;
             Patients are eligible in case therapy is formally indicated but cannot be performed&#xD;
             due to technical or medial reasons if the latter is confirmed in writing by the PI in&#xD;
             mutual agreement with the heart team and Severe aortic stenosis with valve area &lt;&#xD;
             1.5cm² and Severe AR, TR or MR. Classification of severity of regurgitation should&#xD;
             follow the definition provided in Lancelotti et al, Eur Heart J Cardiovasc Imaging&#xD;
             2013 [22]&#xD;
&#xD;
         14. Patients who has unstable and intractable angina pectoris&#xD;
&#xD;
         15. Evidence of right heart failure defined as (by ECHO)&#xD;
&#xD;
               1. Severe Right Ventricular Dysfunction (TAPSE &lt; 14 mm)&#xD;
&#xD;
               2. Severe Right Ventricular Dilatation (RV volume ≥ LV volume)&#xD;
&#xD;
               3. Severe pulmonary hypertension (PASP &gt; 60 mm Hg)&#xD;
&#xD;
         16. Active malignancy&#xD;
&#xD;
         17. Severe valve disease, or implanted mechanical valve prosthesis&#xD;
&#xD;
         18. Congenital heart defect&#xD;
&#xD;
         19. Large PFO with significant atrial septal aneurysm (bubble test shows more than 20&#xD;
             bubbles)&#xD;
&#xD;
         20. Inability to perform 6-minutes walking test&#xD;
&#xD;
         21. Clinically relevant thrombocytopenia, thrombocytosis, leukopenia, or anemia&#xD;
&#xD;
         22. Symptomatic carotid artery disease&#xD;
&#xD;
         23. Mitral valve stenosis&#xD;
&#xD;
         24. Has any condition that, in the opinion of the Investigator, might interfere with the&#xD;
             Implantation, might affect the patients well-being thereafter or might interfere with&#xD;
             the conduct of the study&#xD;
&#xD;
         25. Systolic blood pressure of &gt;170 mmHg, despite medical therapy&#xD;
&#xD;
         26. Severe lung disease (causing PHT with systolic PAP &gt;60mmHg)&#xD;
&#xD;
         27. Pulmonary Hypertension (Systolic PAP &gt;60mmHg)&#xD;
&#xD;
         28. TIA or stroke within the last 6 months&#xD;
&#xD;
         29. Scheduled for heart transplantation&#xD;
&#xD;
         30. Bleeding disorders (INR &gt; 2.0, Thrombocytes &lt; 100.000, Hemoglobin &lt;8.0 gr/dl)&#xD;
&#xD;
         31. Myocardial infarction or percutaneous intervention or CABG (all within the last 3&#xD;
             month) or indication for a coronary intervention&#xD;
&#xD;
         32. Resyncronization therapy started within the last 6 months&#xD;
&#xD;
         33. Aneurysm of the septum&#xD;
&#xD;
         34. Hypertrophied Inter Atrial Septum (IAS) &gt; 10mm depth&#xD;
&#xD;
         35. Hypertrophic Obstructive Cardiomyopathy (HOCM) or infiltrative CM as cause of HF&#xD;
&#xD;
         36. Thromboembolic events within the last 6 months&#xD;
&#xD;
         37. Dialysis and renal insufficiency requiring dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiovascular Center Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezmialem University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

